Genelux (NASDAQ:GNLX) Research Coverage Started at Roth Mkm

Roth Mkm initiated coverage on shares of Genelux (NASDAQ:GNLX) in a research note released on Tuesday morning, Benzinga reports. The firm issued a buy rating and a $10.00 price objective on the stock.

A number of other analysts have also recently commented on the company. Benchmark reduced their price target on Genelux from $30.00 to $25.00 and set a speculative buy rating for the company in a research report on Friday, May 31st. HC Wainwright reiterated a buy rating and set a $32.00 price objective on shares of Genelux in a research note on Thursday, August 15th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Genelux presently has an average rating of Buy and an average target price of $26.75.

Genelux Price Performance

Shares of GNLX stock opened at $2.09 on Tuesday. Genelux has a 1 year low of $1.60 and a 1 year high of $30.44. The firm has a fifty day moving average price of $2.12 and a 200-day moving average price of $3.87. The company has a market cap of $71.80 million, a price-to-earnings ratio of -2.15 and a beta of -1.57.

Insider Buying and Selling at Genelux

In related news, major shareholder Aladar Szalay sold 51,630 shares of the stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $2.11, for a total transaction of $108,939.30. Following the completion of the sale, the insider now owns 1,048,191 shares in the company, valued at $2,211,683.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 108,936 shares of company stock valued at $237,228 over the last ninety days. 9.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Genelux

A number of institutional investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund boosted its position in shares of Genelux by 17.6% during the fourth quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock worth $91,000 after acquiring an additional 966 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Genelux by 216.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock valued at $41,000 after purchasing an additional 2,021 shares during the last quarter. Woodward Diversified Capital LLC grew its position in shares of Genelux by 0.3% during the first quarter. Woodward Diversified Capital LLC now owns 1,085,957 shares of the company’s stock valued at $6,983,000 after purchasing an additional 3,687 shares in the last quarter. LifeSteps Financial Inc. increased its holdings in shares of Genelux by 26.6% in the first quarter. LifeSteps Financial Inc. now owns 44,309 shares of the company’s stock worth $285,000 after purchasing an additional 9,301 shares during the last quarter. Finally, Apollon Wealth Management LLC purchased a new stake in shares of Genelux in the fourth quarter worth about $196,000. 37.33% of the stock is owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.